Nymox

Nymox

March 22, 2005 11:26 ET

Nymox Drug For Benign Prostatic Hyperplasia Holds Promise For Highly Prevalent Problem


NEWS RELEASE TRANSMITTED BY CCNMatthews

FOR: NYMOX

NASDAQ SYMBOL: NYMX

MARCH 22, 2005 - 11:26 ET

Nymox Drug For Benign Prostatic Hyperplasia Holds
Promise For Highly Prevalent Problem

MAYWOOD, N.J.--(CCNMatthews - Mar 22, 2005) -

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) reported today that its
lead drug candidate NX-1207 for the treatment of benign prostatic
hyperplasia (BPH) shows good promise as a potential first-line treatment
for BPH. In two completed trials in the U.S. to date, the drug has shown
highly significant efficacy without significant side effects. The
Company's large Phase 2 trial is expected to be completed later this
year.

In the Phase 1-2 trials to date, after 30 days, the subjects treated
with NX-1207 showed a statistically significant overall mean symptom
improvement of 6.87 points (compared to 0.5 for controls) and a
statistically significant shrinkage in prostate size. There were no
significant adverse side effects from the drug in these trials. Subjects
followed up after one year also showed a statistically significant
symptom improvement of 8.8 points compared to controls.

Symptom improvement was measured using a standard and widely accepted
BPH symptom score rating scale (American Urological Association, AUA BPH
Symptom Score). The AUA BPH symptom score measurement includes data on
1) sensations of incomplete emptying of the bladder; 2) need to urinate
frequently; 3) stopping and starting during urination; 4) urgent need to
urinate; 5) weakness of urinary stream; 6) need to push or strain during
urination; and 7) urination during sleep (nocturia).

BPH afflicts approximately half of men over age 50 and close to 90% of
men by age 80. The disorder causes difficulties with urination
associated with aging, such as urination at night, urge to void
frequently, hesitancy, weak stream, and other problems.

Nymox Pharmaceutical Corporation is a biopharmaceutical company with
three unique proprietary products on the market, and a significant R&D
pipeline of drug products in development. Nymox developed and is
currently offering its AlzheimAlert™ test, a nationally certified
clinical reference laboratory urinary test that is the world's only
accurate, non-invasive aid in the diagnosis of Alzheimer's disease. The
AlzheimAlert™ test is certified with a CE Mark, making the device
eligible for sale in the European Union. Nymox has signed a distribution
deal in Italy for AlzheimAlert™ with Alifax S.p.A. Nymox also
developed and markets NicAlert™ and TobacAlert™ tests that use
urine or saliva to detect use of and exposure to tobacco products.
NicAlert™ has received clearance from the U.S. Food and Drug
Administration (FDA). TobacAlert™ is the first test of its kind to
accurately measure second hand smoke exposure in individuals. The
Company's TobacAlert™ product is presently available in CVS /
pharmacy® stores across the U.S.

In addition to NX-1207, Nymox also has several other drug candidates and
diagnostic technologies in development. Nymox has U.S. and global patent
rights for the use of statin drugs for the treatment and prevention of
Alzheimer's disease. The Company is developing new antibacterial agents
for the treatment of urinary tract and other bacterial infections in
humans and for the treatment of E. coli O157:H7 contamination in meat
and other food and drink products. Nymox also is developing drug
treatments aimed at the causes of Alzheimer's disease.

More information about Nymox is available at www.nymox.com, email:
info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as
defined in the United States Private Securities Litigation Reform Act of
1995 that involve a number of risks and uncertainties. There can be no
assurance that such statements will prove to be accurate and the actual
results and future events could differ materially from management's
current expectations. The conduct of clinical trials and the development
of drug products involve substantial risks and uncertainties and actual
results may differ materially from expectations. Promising early results
do not ensure that later stage or larger scale clinical trials will be
successful or will proceed as expected. Such factors are detailed from
time to time in Nymox's filings with the United States Securities and
Exchange Commission and other regulatory authorities.

-30-

Contact Information

  • FOR FURTHER INFORMATION PLEASE CONTACT:
    Nymox Pharmaceutical Corporation
    Roy Wolvin, 1-800-93NYMOX
    www.nymox.com